Ipilimumab- and Nivolumab-Induced Colitis Causing Severe Hypokalemia and QTc Prolongation
Joint Authors
Chaucer, Benjamin
Anson, David
Norton, Joseph
Bansal, Saurabh
Source
Case Reports in Oncological Medicine
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-2, 2 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-12-27
Country of Publication
Egypt
No. of Pages
2
Main Subjects
Abstract EN
Immune-mediated colitis is an uncommon but well-documented adverse event in patients receiving nivolumab or ipilimumab therapy.
In this report, we present a 69-year-old man who developed severe hypokalemia and colitis with significant corrected Q-T segment (QTc) prolongation as a result of combination nivolumab-ipilimumab immunotherapy for clear cell renal cell carcinoma.
American Psychological Association (APA)
Anson, David& Norton, Joseph& Chaucer, Benjamin& Bansal, Saurabh. 2019. Ipilimumab- and Nivolumab-Induced Colitis Causing Severe Hypokalemia and QTc Prolongation. Case Reports in Oncological Medicine،Vol. 2019, no. 2019, pp.1-2.
https://search.emarefa.net/detail/BIM-1142103
Modern Language Association (MLA)
Anson, David…[et al.]. Ipilimumab- and Nivolumab-Induced Colitis Causing Severe Hypokalemia and QTc Prolongation. Case Reports in Oncological Medicine No. 2019 (2019), pp.1-2.
https://search.emarefa.net/detail/BIM-1142103
American Medical Association (AMA)
Anson, David& Norton, Joseph& Chaucer, Benjamin& Bansal, Saurabh. Ipilimumab- and Nivolumab-Induced Colitis Causing Severe Hypokalemia and QTc Prolongation. Case Reports in Oncological Medicine. 2019. Vol. 2019, no. 2019, pp.1-2.
https://search.emarefa.net/detail/BIM-1142103
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1142103
